Anzeige
Mehr »
Samstag, 12.09.2026 - Börsentäglich über 12.000 News

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3DPNV | ISIN: CA76206T1084 | Ticker-Symbol: 4YX0
Frankfurt
11.09.26 | 20:15
0,006 Euro
+90,00 % +0,003
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
RHELION LIFE SCIENCES CORP Chart 1 Jahr
5-Tage-Chart
RHELION LIFE SCIENCES CORP 5-Tage-Chart

Aktuelle News zur RHELION LIFE SCIENCES Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrRhelion Life Sciences Corp: Rhelion's Filament plans stability program for IBEX0117
DoRhelion Life Sciences Corp.: Rhelion Life Sciences Announces Filament Health is Planning a Stability Program for IBEX011, Its Naturally Derived Ibogaine Drug Candidate186Filament Health has begun planning a stability program for IBEX011, its naturally derived botanical ibogaine drug candidate, in response to growing demand for GMP quality, standardized ibogaine for...
► Artikel lesen
RHELION LIFE SCIENCES Aktie jetzt für 0€ handeln
MiRhelion Life Sciences Corp: Rhelion ships PEX010 to Australia for FND trial3
DiRhelion Life Sciences Corp.: Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Completes Shipment of PEX010 to Australia for University of Melbourne Trial of Psilocybin-Assisted Physiotherapy in Functional Neurological Disorder214Filament Health's patented, naturally derived psilocybin drug candidate PEX010 has been shipped to Austin Health in Melbourne for PSI-PHY, an investigator initiated pilot trial of psilocybin-assisted...
► Artikel lesen
31.08.Red Light Holland reports Q1 results4
28.08.Rhelion Life Sciences Corp: Rhelion's Filament gains new U.S. psilocybin patent11
27.08.Rhelion Life Sciences Corp.: Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Issued New United States Patent, Extending the Broadest Natural Psilocybin Patent Estate858A new United States patent, "Dephosphorylation-Controlled Extraction of Phosphorylatable Psychoactive Alkaloids," issued this month, adding to the intellectual property estate behind PEX010, the...
► Artikel lesen
25.08.Rhelion Life Sciences Corp: Rhelion subsidiary ships psilocybin for cancer trial6
25.08.Rhelion Life Sciences Corp.: Rhelion Life Sciences Wholly Owned Subsidiary Filament Health Completes Shipment of PEX010 for University of Washington Phase 2a Trial in Cancer-Related Anxiety and Depression602Filament Health's patented, naturally derived psilocybin drug candidate PEX010 will be supplied to an investigator initiated Phase 2a study evaluating a group retreat model of psilocybin therapy...
► Artikel lesen
20.08.Rhelion Life Sciences Corp: Rhelion Life Sciences signs LOI with Darmiyan6
20.08.Rhelion Life Sciences Corp.: Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Signs Letter of Intent with Darmiyan, Inc. to Explore Use of FDA De Novo Authorized BrainSee(R) AI Platform in Early Alzheimer's Disease Trial Design1.303Collaboration looks to explore the use of Darmiyan's FDA De Novo authorized BrainSee imaging platform, authorized for predicting risk of progression to Alzheimer's disease in patients with amnestic...
► Artikel lesen
19.08.Rhelion Life Sciences Corp: Rhelion Life Sciences appoints Khaja CFO5
19.08.Rhelion Life Sciences Corp.: Rhelion Life Sciences Announces Appointment of Samiuddin Khaja as CFO480Toronto, Ontario--(Newsfile Corp. - August 19, 2026) - Rhelion Life Sciences Corp. (CSE: RHEL) (FSE: 4YX) (OTCQB: TRUFF) ("Rhelion" or the "Company"), an Ontario-based organization advancing innovation...
► Artikel lesen
14.08.Rhelion Life Sciences Corp: Rhelion subsidiary signs PEX010 licence deal with UHN6
14.08.Rhelion Life Sciences Corp.: Rhelion Life Sciences Signs Agreement with University Health Network for Randomized Clinical Trial of Psilocybin in Parkinson's Disease Depression752Filament Health's patented, naturally derived psilocybin drug candidate PEX010 will be supplied to PSI-PARK, an investigator initiated randomized clinical trial evaluating psilocybin for the treatment...
► Artikel lesen
06.08.Rhelion Life Sciences Corp: Rhelion Life Sciences symbol change8
06.08.XFRA NEW INSTRUMENTS AVAILABLE ON 06.08.2026383The following instruments on XETRA do have their first trading 06.08.2026 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 06.08.2026 Aktien 1 US00827B1061 Affirm Holdings Inc. 2...
► Artikel lesen
05.08.CSE Bulletin: Symbol Change - Rhelion Life Sciences Corp. (RELH)166Le 5 août/August 2026 Rhelion Life Sciences Corp. (RELH) has announced a symbol change to RHEL. Shares will begin trading under the new symbol on August 7, 2026. Disclosure documents are available...
► Artikel lesen
05.08.XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 05.08.2026933The following instruments on Boerse Frankfurt do have their last trading day on 05.08.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 05.08.2026ISIN NameCA75671E1097 RED...
► Artikel lesen
05.08.XFRA ISIN CHANGE533Einstellung Aufnahme ISIN Name Einstellung mit Ablauf: ISIN Name Ab dem: AnmerkungenCA75671E1097 Red Light Holland Corp. 05.08.2026 CA76206T1084 Red Light Holland Corp. 06.08.2026 Tausch 1:1CA89624B5009 Dune...
► Artikel lesen
Weiter >>
77 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1